Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMTX Immatics	$6.12 -0.3%	$4.91	$3.30 ▼ $13.23	$743.89M	0.83	654,063 shs	536,153 shs
IOVA Iovance Biotherapeutics	$2.24 -3.0%	$2.55	$1.64 ▼ $12.51	$748.01M	0.86	8.88 million shs	8.78 million shs
KALV KalVista Pharmaceuticals	$12.96 -1.0%	$12.35	$7.30 ▼ $15.50	$644.32M	-0.01	443,059 shs	768,473 shs
VYGR Voyager Therapeutics	$3.30 -8.3%	$3.26	$2.65 ▼ $9.55	$182.61M	0.82	475,764 shs	913,503 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMTX Immatics	0.00%	+2.51%	+29.11%	+22.89%	-53.00%
IOVA Iovance Biotherapeutics	0.00%	+9.27%	+34.94%	-40.11%	-72.55%
KALV KalVista Pharmaceuticals	0.00%	-9.75%	+8.63%	+3.76%	+7.37%
VYGR Voyager Therapeutics	0.00%	-6.78%	0.00%	-15.17%	-61.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMTX Immatics	2.6055 of 5 stars	3.6	3.0	0.0	3.4	1.7	0.0
IOVA Iovance Biotherapeutics	4.6382 of 5 stars	4.3	1.0	4.2	2.2	4.2	1.3
KALV KalVista Pharmaceuticals	3.971 of 5 stars	3.6	0.0	4.4	3.1	2.5	0.6
VYGR Voyager Therapeutics	4.4133 of 5 stars	3.6	1.0	4.6	3.2	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMTX Immatics	3.20	Buy	$14.67	139.65% Upside
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$13.30	493.75% Upside
KALV KalVista Pharmaceuticals	3.13	Buy	$24.83	91.62% Upside
VYGR Voyager Therapeutics	3.13	Buy	$13.39	305.76% Upside

Current Analyst Ratings Breakdown

Latest VYGR, IOVA, KALV, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	IMTX Immatics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00
5/12/2025	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $10.00
5/12/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/12/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
5/9/2025	IOVA Iovance Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $20.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMTX Immatics	$144.15M	5.16	N/A	N/A	$2.88 per share	2.13
IOVA Iovance Biotherapeutics	$212.68M	3.52	N/A	N/A	$2.28 per share	0.98
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A
VYGR Voyager Therapeutics	$66.96M	2.73	$2.34 per share	1.41	$5.37 per share	0.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMTX Immatics	-$104.98M	-$0.17	N/A	N/A	N/A	-47.94%	-15.90%	-9.38%	8/12/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$444.04M	-$1.24	N/A	N/A	N/A	-451.25%	-58.43%	-45.48%	8/6/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-103.92%	-88.06%	7/10/2025 (Estimated)
VYGR Voyager Therapeutics	$132.33M	-$1.46	4.65	N/A	N/A	15.80%	8.33%	6.15%	8/5/2025 (Estimated)

Latest VYGR, IOVA, KALV, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	IMTX Immatics	-$0.39	-$0.35	+$0.04	-$0.35	$14.92 million	$20.12 million
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million
3/27/2025	Q4 2024	IMTX Immatics	-$0.03	$0.48	+$0.51	$0.48	$16.16 million	$15.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMTX Immatics	N/A	3.98	3.98
IOVA Iovance Biotherapeutics	N/A	4.22	3.90
KALV KalVista Pharmaceuticals	N/A	6.87	6.87
VYGR Voyager Therapeutics	N/A	8.45	8.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMTX Immatics	64.41%
IOVA Iovance Biotherapeutics	77.03%
KALV KalVista Pharmaceuticals	N/A
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
IMTX Immatics	3.30%
IOVA Iovance Biotherapeutics	10.30%
KALV KalVista Pharmaceuticals	10.50%
VYGR Voyager Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMTX Immatics	260	121.55 million	115.42 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	267.90 million	Optionable
KALV KalVista Pharmaceuticals	100	49.72 million	44.23 million	Optionable
VYGR Voyager Therapeutics	100	55.34 million	52.15 million	Optionable

VYGR, IOVA, KALV, and IMTX Headlines

Recent News About These Companies

Voyager Technologies Soars with IPO Success

June 14 at 3:45 PM | devdiscourse.com

Space Tech Ventures Surge: Voyager's IPO Success and Starlink's Swiss Expansion

June 12, 2025 | devdiscourse.com

Voyager Technologies Rises in Debut, Signaling Improving IPO Market

June 12, 2025 | msn.com

Cantor Fitzgerald Estimates VYGR FY2026 Earnings

June 12, 2025 | americanbankingnews.com

Voyager soars 82% on first day of trading as defense tech booms

June 12, 2025 | msn.com

Investor demand for Voyager’s stock keeps growing, despite a mixed history for space-tech IPOs

June 11, 2025 | msn.com

Voyager Technologies' Shares More Than Double in NYSE Debut

June 11, 2025 | marketwatch.com

Voyager Technologies Shares Soar In Market Debut

June 11, 2025 | news.crunchbase.com

Space tech firm Voyager valued at $3.8 billion as shares surge in NYSE debut

June 11, 2025 | aol.com

Voyager raises $383 million from upsized IPO

June 11, 2025 | spacenews.com

Space and defense tech firm Voyager raises $382.8 million in IPO

June 11, 2025 | fastcompany.com

Voyager Technologies Valued at $3.8 Billion in Stellar NYSE Debut

June 11, 2025 | msn.com

Voyager Technologies’ IPO shows investors are still hot on space stocks, despite a mixed history

June 11, 2025 | marketwatch.com

Voyager Announces Pricing of Initial Public Offering

June 10, 2025 | bakersfield.com

Brokers Issue Forecasts for VYGR FY2026 Earnings

June 10, 2025 | marketbeat.com

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 10, 2025 | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Recommendation of "Buy" by Analysts

June 10, 2025 | americanbankingnews.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Buy" from Analysts

June 10, 2025 | marketbeat.com

Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)

June 7, 2025 | seekingalpha.com

Voyager Technologies, Inc. Announces Launch of Initial Public Offering

June 3, 2025 | finanznachrichten.de

Space Firm Voyager Technologies Seeks $1.6 Billion Valuation in IPO

June 2, 2025 | theinformation.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR, IOVA, KALV, and IMTX Company Descriptions

Immatics NASDAQ:IMTX

$6.12 -0.02 (-0.33%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$6.16 +0.04 (+0.65%)

As of 06:21 AM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Iovance Biotherapeutics NASDAQ:IOVA

$2.24 -0.07 (-3.03%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.21 -0.03 (-1.34%)

As of 07:01 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

KalVista Pharmaceuticals NASDAQ:KALV

$12.96 -0.13 (-0.99%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$12.35 -0.61 (-4.70%)

As of 07:04 AM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Voyager Therapeutics NASDAQ:VYGR

$3.30 -0.30 (-8.33%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.38 +0.08 (+2.42%)

As of 06:42 AM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time